サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1672040

発作性夜間ヘモグロビン尿症（PNH）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日
ページ情報
英文 131 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
発作性夜間ヘモグロビン尿症（PNH）治療の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2025年～2033年）
出版日: 2025年03月01日
発行: Value Market Research
ページ情報: 英文 131 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の発作性夜間ヘモグロビン尿症（PNH）治療の市場規模は、2024年の48億8,000万米ドルから2033年には133億1,000万米ドルに成長し、2026年～2033年の予測期間中に11.77％の堅調なCAGRを示すと予測されます。

発作性夜間ヘモグロビン尿症（PNH）治療市場は、疾患に対する理解の深まりと標的治療の開発により、著しい進歩を遂げています。PNHは、赤血球の破壊を特徴とする希少で衰弱性の血液疾患であり、その複雑な性質のため、歴史的に治療に課題がありました。しかし、補体阻害薬などのモノクローナル抗体治療における最近の画期的な進歩は、この疾患の管理に革命をもたらし、患者に転帰と生活の質の向上をもたらしています。

PNHの有病率の増加は、ヘルスケア専門家の意識の高まりと相まって、効果的な治療オプションに対する需要を後押ししています。診断技術が向上するにつれ、より多くの患者が特定され、治療されるようになり、市場の成長をさらに促進しています。さらに、現在進行中の臨床試験や研究イニシアチブは、併用療法や新規治療法の探索に重点を置いており、PNHの治療展望を拡大すると期待されています。既存の治療法では十分な効果が得られない患者のアンメットニーズに対応するため、このような技術革新への注力は極めて重要です。

さらに、個別化医療が重視されるようになり、PNH治療市場に影響を与えています。個々の患者のプロファイルや遺伝子マーカーに基づいて治療計画を調整することはますます可能になってきており、より効果的で的を絞った治療が可能となってきています。製薬企業と研究機関の協力により、有効性の向上と副作用の最小化を目指した次世代治療法の開発が促進されています。結論として、PNH治療市場は、技術革新、認知度の向上、この困難な治療分野における患者の転帰改善へのコミットメントを特徴とし、力強い成長を遂げようとしています。

当社のレポートは、様々な産業や市場に関する包括的かつ実用的な洞察をお客様に提供するために、細心の注意を払って作成されています。各レポートには、市場情勢を完全に理解するためのいくつかの重要な要素が含まれています：

市場概要：定義、分類、業界の現状など、市場に関する詳細なイントロダクションです。

市場促進要因：市場成長に影響を与える主な促進要因・抑制要因・機会・課題を詳細に分析します。このセクションでは、技術の進歩、規制の変更、新たな動向などの要因を検証します。

セグメンテーション分析：製品タイプ、用途、エンドユーザー、地域などの基準に基づき、市場を明確なセグメントに分けています。この分析により、各セグメントの業績と将来性を明らかにします。

競合情勢：市場シェア、製品ポートフォリオ、戦略的イニシアティブ、財務実績など、主要市場企業の包括的評価です。主要企業が採用する競合力学と主要戦略に関する考察を提供します。

市場予測：実績データと現在の市場状況に基づき、一定期間における市場規模と成長動向を予測します。これには、定量的分析と将来の市場軌跡を示すグラフ表示が含まれます。

地域分析：地域ごとの市場パフォーマンスを評価し、主要市場や地域動向を明らかにします。地域の市場力学とビジネスチャンスを理解するのに役立ちます。

新たな動向と機会：現在の市場動向と新たな市場動向、技術革新、潜在的な投資対象分野を特定します。将来の市場開拓と成長見通しに関する洞察を提供します。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 発作性夜間ヘモグロビン尿症（PNH）治療の産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：治療タイプ別

  • 治療タイプ別の概要
  • 治療タイプ別の実績・予測データ分析
  • 補体阻害薬
  • 鉄療法
  • 免疫抑制剤
  • 骨髄移植
  • その他

第6章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：投与経路別

  • 投与経路別の概要
  • 投与経路別の実績・予測データ分析
  • 経口
  • 非経口

第7章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：年齢層別

  • 年齢層別の概要
  • 年齢層別の実績・予測データ分析
  • 小児
  • 成人

第8章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：最終用途別

  • 最終用途別の概要
  • 最終用途別の実績・予測データ分析
  • 病院
  • 専門クリニック
  • 在宅医療
  • その他

第9章 発作性夜間ヘモグロビン尿症（PNH）治療の世界市場分析：地域別

  • 地域別の展望
  • イントロダクション
  • 北米の売上分析
    • 概要・実績・予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要・実績・予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要・実績・予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要・実績・予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要・実績・予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第10章 発作性夜間ヘモグロビン尿症（PNH）治療企業の競合情勢

  • 発作性夜間ヘモグロビン尿症（PNH）治療市場競合
  • 提携・協力・合意
  • 合併・買収
  • 新製品上市
  • その他の開発

第11章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Children'S National Hospital
  • F. Hoffmann-La Roche Ltd.
  • Memorial Sloan Kettering Cancer Center
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • UCLA Health
  • University Of Rochester Medical Center
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty clinics Market Sales By Geography (USD MN)
  • Homecare settings Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty clinics Market Sales By Geography (USD MN)
  • Homecare settings Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
目次
Product Code: VMR11210464

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size is anticipated to grow from USD 4.88 Billion in 2024 to USD 13.31 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 11.77% during the forecast period of 2026 to 2033.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is experiencing significant advancements, driven by a deeper understanding of the disease and the development of targeted therapies. PNH, a rare and debilitating blood disorder characterized by the destruction of red blood cells, has historically posed challenges in treatment due to its complex nature. However, recent breakthroughs in monoclonal antibody therapies, such as complement inhibitors, have revolutionized the management of this condition, offering patients improved outcomes and quality of life.

The increasing prevalence of PNH, coupled with heightened awareness among healthcare professionals, is propelling the demand for effective treatment options. As diagnostic techniques improve, more patients are being identified and treated, further driving market growth. Additionally, ongoing clinical trials and research initiatives are focused on exploring combination therapies and novel treatment modalities, which are expected to expand the therapeutic landscape for PNH. This focus on innovation is crucial, as it addresses the unmet needs of patients who may not respond adequately to existing therapies.

Furthermore, the growing emphasis on personalized medicine is influencing the PNH treatment market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The collaboration between pharmaceutical companies and research institutions is fostering the development of next-generation therapies that aim to enhance efficacy and minimize side effects. In conclusion, the PNH treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient outcomes in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Treatment Type

  • Complement Inhibitors
  • Iron Therapy
  • Immunosuppressant Drugs
  • Bone Marrow Transplantation
  • Other Treatment Types

By Route Of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adult

By End-use

  • Hospitals
  • Specialty clinics
  • Homecare settings
  • Other end-users
  • COMPANIES PROFILED
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Children's National Hospital
  • F. Hoffmann-La Roche Ltd.
  • Memorial Sloan Kettering Cancer Center
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • UCLA Health
  • University of Rochester Medical Center
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Complement Inhibitors Historic and Forecast Sales By Regions
  • 5.4. Iron Therapy Historic and Forecast Sales By Regions
  • 5.5. Immunosuppressant Drugs Historic and Forecast Sales By Regions
  • 5.6. Bone Marrow Transplantation Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route of Administration
  • 6.2. Historical and Forecast Data Analysis By Route of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY AGE GROUP

  • 7.1. Overview By Age Group
  • 7.2. Historical and Forecast Data Analysis By Age Group
  • 7.3. Pediatric Historic and Forecast Sales By Regions
  • 7.4. Adult Historic and Forecast Sales By Regions

8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-use
  • 8.2. Historical and Forecast Data Analysis By End-use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty clinics Historic and Forecast Sales By Regions
  • 8.5. Homecare settings Historic and Forecast Sales By Regions
  • 8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

  • 10.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Amgen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Apellis Pharmaceuticals Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. AstraZeneca Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Children'S National Hospital
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Memorial Sloan Kettering Cancer Center
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Novartis AG
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Pfizer Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Regeneron Pharmaceuticals Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Teva Pharmaceuticals Industries Ltd.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. UCLA Health
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. University Of Rochester Medical Center
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies